Targeting gallbladder carcinoma: Bone marrow-derived stem cells as therapeutic delivery vehicles of myxoma virus

Chinese Medical Journal

Volumn 127, Issue 12, 2014, Pages 2350-2356

  Weng, Ming Zhe ^a   Zhang, Ming Di ^a   Qin, Yi Yu ^a   Gong, Wei ^a   Tang, Zhao Hui ^a   Quan, Zhi Wei ^a   Wu, Ke Jin ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bone marrow derived stem cells; Gallbladder carcinoma; Myxoma virus; Oncolytic virotherapy

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GALLBLADDER CARCINOMA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MYXOMA VIRUS; ONCOLYTIC VIROTHERAPY; QUANTITATIVE ASSAY; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ANIMAL; BONE MARROW CELL; CELL MOTION; CELL SURVIVAL; CYTOLOGY; DRUG SCREENING; FEMALE; GALLBLADDER NEOPLASMS; IMMUNOHISTOCHEMISTRY; MOUSE; PATHOGENICITY; PHYSIOLOGY; STEM CELL; VIROLOGY;

ANIMALS; BONE MARROW CELLS; CELL MOVEMENT; CELL SURVIVAL; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MYXOMA VIRUS; STEM CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902449591     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132704     Document Type: Article

References (20)

1. Dutt UJ. Gall bladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 2012; 27: 642-653.
2. Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978; 147: 929-942.
3. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012; 18: 771-781.
4. Wang F, Ma Y, Barrett JW, Gao X, Loh J, Barton E, et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 2004; 5: 1266-1274.
5. Stanford MM, Werden SJ, McFadden G. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res 2007; 38: 299-318.
6. Kerr PJ, Ghedin E, DePasse J V, Fitch A, Cattadori IM, Hudson PJ, et al. Evolutionary history and attenuation of myxoma virus on two continents. PLoS Pathog 2012; 8: e1002950.
7. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005; 65: 9982-9990.
8. Brower V. Search and destroy: recent research exploits adult stem cells' attraction to cancer. J Natl Cancer Inst 2005; 97: 414-416.
9. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007; 15: 660-665.
10. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009; 17: 1667-1676.
11. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
12. Woo Y, Kelly KJ, Stanford MM, Galanis C, Chun YS, Fong Y, et al. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol 2008; 15: 2329-2335.
13. Smallwood SE, Rahman MM, Smith DW, McFadden G. Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol. Gainesville: Wiley-Liss, lnc., 2010: 1-24.
14. Sasser AK, Mundy BL, Smith KM, Studebaker AW, Axel AE, Haidet AM, et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett 2007; 254: 255-264.
15. Aung W, Sogawa C, Furukawa T, Saga T. Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res 2011; 31: 1549-1558.
16. Feng FL, Liu C, Li B, Zhang BH, Jiang XQ. Role of radical resection in patients with gallbladder carcinoma and jaundice. Chin Med J 2012; 125: 752-756.
17. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 2006; 103: 4640-4645.
18. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004; 96: 1593-1603.
19. Eom YW, Oh JE, Lee JI, Baik SK, Rhee KJ, Shin HC, et al. The role of growth factors in maintenance of stemness in bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun 2014; 445: 16-22.
20. Zhao YH, Yang Q, Xia Q, Peng J, Lu SB, Guo QY, et al. In vitro cartilage production using an extracellular matrix-derived scaffold and bone marrow-derived mesenchymal stem cells. Chin Med J 2013; 126: 3130-3137.